Effects of recombinant human growth hormone in catabolic adults with chronic renal failure.
Growth hormone (GH) has been used for the treatment of catabolism in a few pilot studies and in two placebo-controlled studies of 6 months duration. Treatment with GH in doses of 2-4 IU/m2/day (0.67-1.33 mg/m2/day) resulted in clear anabolic effects and a significant change in body composition. Lean body mass increased by more than 3 kg within 6 months, whereas fat mass was decreased by the same amount, resulting in a constant total body weight. As there were no major side-effects, controlled long-term studies are justified.
Mehls
O
O
Division of Pediatric Nephrology, University Children's Hospital of Germany, Heidelberg.
Haas
S
S
D000328:Adult; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D005947:Glucose / Q000378:metabolism; D006410:Hematopoiesis / Q000187:drug effects; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D009584:Nitrogen / Q000378:metabolism; D010865:Pilot Projects; D010919:Placebos; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014511:Uremia / Q000188:drug therapy
D010919:Placebos; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D005947:Glucose; D009584:Nitrogen